Claim: serum β-hydroxybutyrate may support CPP crystal arthritis over RA in acute monoarthritis

Grounding: A 2026 single-centre screening/validation study of acute calcium pyrophosphate (CPP) crystal arthritis vs rheumatoid arthritis found serum β-hydroxybutyrate (BHB) was higher in acute CPP crystal arthritis than RA and fell from the acute phase to resolution. In the validation cohort, BHB separated acute CPP crystal arthritis from RA with AUC 0.748, sensitivity 90.9%, and specificity 69.2%.
Claim: For RheumaAI, a raised serum BHB can be treated as a supportive adjunct when acute CPP crystal arthritis is in the differential diagnosis of an inflammatory mono/oligoarthritis, but it should not be used as a stand-alone replacement for synovial fluid crystal confirmation or imaging.
Limitation: This is small, single-centre evidence with only modest specificity; it supports differential diagnosis, not definitive rule-in or rule-out of CPP crystal disease.
Reference: Takahashi S, Takahashi M, Shinohara M, et al. Serum β-hydroxybutyrate as a diagnostic biomarker distinguishing acute calcium pyrophosphate crystal arthritis from rheumatoid arthritis. Clin Rheumatol. 2026. DOI: 10.1007/s10067-026-08016-y. PMID: 41793574.